A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings ...
INDIANAPOLIS, Indiana: This week, Eli Lilly said that after conducting two late-stage trials, its weight-loss drug Zepbound has been proven to reduce sleep apnea episodes, paving the way for its ...
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms for people with obesity. The drug improved sleep apnea symptoms whether or not people used a PAP machine.
Zepbound, a popular weight loss drug from Eli Lilly, may help people with sleep apnea. Based on recent findings, Eli Lilly plans to submit the material to the U.S. Food and Drug Administration to ...
Eli Lilly’s weight loss drug Zepbound has been shown to “significantly reduce” obstructive sleep apnea (OSA) in adults with obesity, the company said Wednesday. Injections of tirzepatide ...
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.
The diabetes and weight loss drug tirzepatide appears to help people with obesity who also have sleep apnea, according to preliminary findings from drugmaker Eli Lilly. The results, while ...
Zepbound, a drug that rivals Ozempic, may one day be a treatment for sleep apnea, according to results from a new study. Jessica is a writer on the Wellness team with a focus on health news.
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructive sleep apnea affects about 39 ...